Financhill
Back

Janux Therapeutics Quote, Financials, Valuation and Earnings

Sell
43

JANX
Janux Therapeutics

Last Price:
45.37
Seasonality Move:
8.69%

7 Day Trial

ALL ACCESS PASS

$ 7

Janux Therapeutics Price Quote

$45.37

Janux Therapeutics Key Stats

Sell
43
Janux Therapeutics (JANX) is a Sell

Day range:
$42.70 - $45.40
52-week range:
$5.65 - $65.60
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
285.33
P/B ratio:
3.59%

Volume:
692K
Avg. volume:
828K
1-year change:
253.07%
Market cap:
$2.4B
Revenue:
$8.1M
EPS:
$-1.21

How Much Does Janux Therapeutics Make?

Is Janux Therapeutics Growing As A Company?

  • What Is Janux Therapeutics's Growth Rate Quarterly?
    Quarterly YoY revenue growth is -0.39%
  • What Is Janux Therapeutics's EPS Quarterly YoY Growth Rate?
    Quarterly, year-over-year diluted EPS growth rate is 0%

Janux Therapeutics Stock Price Performance

What Is Janux Therapeutics 52-Week High & Low?

Janux Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Janux Therapeutics?

Is Janux Therapeutics Cash Flow Positive?

  • What Is JANX Cash Flow From Operations?
    Cash flow from operations (TTM) is -$51.5M
  • What Is Janux Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $380.1M
  • What Is Janux Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is -$146.2M

Janux Therapeutics Return On Invested Capital

  • Is Management Doing A Good Job?
    JANX return on invested capital is -14.18%
  • What Is Janux Therapeutics Return On Assets?
    ROA measures how assets are converting to revenues and is -12.93%
  • What Is JANX Return On Equity?
    ROE is a measure of profitability and is -14.18%

Janux Therapeutics Earnings Date & Stock Price

Janux Therapeutics Competitors

  • Who Are Janux Therapeutics's Competitors?
    Below is a list of companies who compete with Janux Therapeutics or are related in some way:
    • Arvinas Inc (ARVN)
    • Calidi Biotherapeutics Inc (CLDI)
    • Equillium Inc (EQ)
    • Minerva Neurosciences Inc (NERV)
    • Viking Therapeutics Inc (VKTX)

Janux Therapeutics Dividend Yield

Data Unavailable

Janux Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 9.09%
Revenue: -38.87% 23.01%

Analyst Recommendations

Buy Recommendations: 8
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 63.57
Upside from Last Price: 40.12%

Major Shareholders

  • How many JANX shares are owned by institutional investors?
    63.3M JANX shares are owned by institutional investors
  • How many JANX shares are owned by insiders?
    935.6K JANX shares are owned by insiders